Actuate Therapeutics, Inc. (ACTU)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	195.91M
Revenue (ttm)	n/a
Net Income (ttm)	-27.77M
Shares Out	21.77M
EPS (ttm)	-1.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ACTU

Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β. We believe that the blockade of GSK-3β signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a po...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: ACTU

Financial Performance

Financial numbers in USD